{"article_title": "Why Auxilium Pharmaceuticals Wants QLT, Inc. -- The Motley Fool", "article_keywords": ["wants", "fool", "williamson", "testosterone", "motley", "testim", "qlt", "treatments", "pharmaceuticals", "strange", "video", "stendra", "auxilium", "today"], "article_url": "http://www.fool.com/investing/general/2014/06/26/why-auxilium-pharmaceuticals-wants-qlt-inc.aspx", "article_text": "Auxilium Pharmaceuticals (NASDAQ:AUXL) shares were down a bit today on news that it is looking to merge -- in a $354 million, all-stock deal -- with Canada-based QLT (NASDAQ:QLTI). Auxilium, which is well known for its testosterone treatments (like Testim) and erectile dysfunction drugs like Stendra, seems like a somewhat strange fit for QLT, which has a small pipeline focused on a pair of eye conditions.\n\nSo, why does Auxilium want QLT?\n\nIn the video below, health care analysts Michael Douglass and David Williamson answer.", "article_metadata": {"publish_time": "17:01", "date": "2014-06-26T21:01:00Z", "description": "Small deal, but part of a larger trend.", "ResponsiveALP": "1Ses_2things-v-single_single-control_50", "author": "Michael Douglass and Dave Williamson", "promo": "Small deal, but part of a larger trend.", "twitter": {"site": "@themotleyfool", "description": "Small deal, but part of a larger trend.", "title": "Why Auxilium Pharmaceuticals Wants QLT, Inc. --  The Motley Fool"}, "og": {"site_name": "The Motley Fool", "description": "Small deal, but part of a larger trend.", "title": "Why Auxilium Pharmaceuticals Wants QLT, Inc. --  The Motley Fool", "url": "http://www.fool.com/investing/general/2014/06/26/why-auxilium-pharmaceuticals-wants-qlt-inc.aspx", "image": "https://g.foolcdn.com/image/?url=http%3A%2F%2Fg.foolcdn.com%2Fassets%2Fimages%2Ffool%2Ftmf-logo.png&h=630&w=1200&op=resize", "type": "article"}, "headline": "Why Auxilium Pharmaceuticals Wants QLT, Inc.", "fb": {"admins": 50808187550, "page_id": 7240312795, "app_id": 50808187550}, "bureau": "usmf-health-care", "STORY_UID": "66ef264e-fd70-11e3-ae39-0050569d32b9", "pitch": 823, "msvalidate.01": "8D40D58712924715BAA79D135A6C8DDA", "gsa_date": "2014 06 26", "tickers": "AUXL,QLTI", "viewport": "width=device-width, initial-scale=1.0, maximum-scale=1.0"}, "article_summary": "Auxilium Pharmaceuticals (NASDAQ:AUXL) shares were down a bit today on news that it is looking to merge -- in a $354 million, all-stock deal -- with Canada-based QLT (NASDAQ:QLTI).\nSo, why does Auxilium want QLT?\nAuxilium, which is well known for its testosterone treatments (like Testim) and erectile dysfunction drugs like Stendra, seems like a somewhat strange fit for QLT, which has a small pipeline focused on a pair of eye conditions.\nIn the video below, health care analysts Michael Douglass and David Williamson answer."}